



Priority Docket No.: 3985,240-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Havelund et al.

Serial No.: 09/398,365

Group Art Unit: 1646

Filed: September 17, 1999

Examiner: C. Saoud

Confirmation No: 9987

For: Acylated Insulin

RECEIVED

JUL 17 2001

TECH CENTER 1601 BLD.

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed 17 January 2001.

It is respectfully requested that the time for response to the Office Action dated 17 January 2001 be extended for a period of 3 months from April 17, 2001 to July 17, 2001. The required fee for the extension is estimated to be \$890.

No additional claims fee is required

In the event that an extension of time is required, Applicant hereby petitions for such extension of time. The Commissioner of Patents is authorized to charge the required fee if applicable, to Deposit Account No. 14-1447.

Please charge the required extension fee, estimated to be \$890, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: 06 July 2001

*Valeta G. Gregg*  
Valeta A. Gregg, Reg. No. 35,127  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE